Dynavax to Present at the 7th Annual JMP Securities Healthcare Conference
(firmenpresse) - BERKELEY, CA -- (Marketwire) -- 07/09/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the 7th Annual JMP Securities Healthcare Conference in New York on Thursday, July 12, at 10:00 a.m. EDT (7:00 a.m. PDT).
Tyler Martin, M.D., President and Chief Medical Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at .
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. A U.S. BLA for HEPLISAV has been accepted for review by the FDA. For more information visit .
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2012 - 07:00 Uhr
Sprache: Deutsch
News-ID 1131012
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BERKELEY, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 111 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dynavax to Present at the 7th Annual JMP Securities Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Dynavax Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
